The tumor size measurements indicated britanin treatment inhibited tumor growth by upregulating the expression of Bax and downregulating the expression of Bcl-2, and suppressing NF-κB activation, which is related to a decrease in nuclear p65 levels. This evidence concerns the gene BCL2 and neoplasm.